Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Urinary Bladder Neoplasms

abstract

  • In our experience intravesical gemcitabine should be considered after bacillus Calmette-Guérin failure in patients with bladder cancer who refuse radical cystectomy or who are not candidates for major surgery.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.juro.2013.04.120

PubMed ID

  • 23665400

Additional Document Info

start page

  • 1686

end page

  • 91

volume

  • 190

number

  • 5